Bayer implements artificial intelligence for search of new drugs for cancer therapy and heart troubles

At the end of January, 2020 Bayer announced cooperation with the Exscientia company which is engaged in search of drugs using artificial intelligence. Within this partnership the German giant implements solutions of the partner to investigate connections which potentially could become drugs for therapy of cardiovascular and oncological diseases.

Besides, the companies will work jointly on the early research projects combining the Exscientia platform on search of drugs with Bayer opportunities for data collection. Exscientia will also receive from Bayer up to $266 million investments for development of new projects. The companies consider that the artificial intelligence is capable to accelerate search of drugs and to improve quality of their development, having at the same time reduced the cost of researches.

Bayer announced cooperation with the Exscientia company which is engaged in search of drugs using artificial intelligence

Within cooperation of the company intend to use an algorithm on the basis of AI for forecasting of potential properties of new connections. Recently updated Excientia platform allows to estimate new chemicals and to identify candidates for medicines. At the same time Bayer reserves the right to production of all new drugs developed within cooperation though Exscientia can also receive license fees from sales.

We advance digital transformation in the field of research and development as we consider that digital technologies, such as artificial intelligence, are capable to simplify and accelerate search and development of new drugs for rare or incurable diseases — the head of pharmaceutical division of Bayer of research and development, the member of executive committee doctor Joerg Moeller noted. — It is expected that cooperation with Exscientia will help us to implement quicker the project and to reveal chemical formulas from the greatest potential.[1]

Notes